SYS6010
Sponsors
CSPC Megalith Biopharmaceutical Co.,Ltd., Fujian Cancer Hospital, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Sichuan University
Conditions
Advanced Solid TumorsColorectal CancerEGFR-mutated Locally Advanced or Metastatic NSCLCGastric Cancer (GC)Gastrointestinal TumorsLocally Advanced/Metastatic/Recurrent ESCCNSCLCNon-Small Cell Lung Cancer
Phase 1
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
RecruitingNCT07241936
Start: 2025-11-13End: 2028-10-30Target: 444Updated: 2025-11-28
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Not yet recruitingNCT07692048
Start: 2026-06-30End: 2028-12-31Target: 21Updated: 2026-07-09
Phase 2
Phase 3
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
RecruitingNCT06927986
Start: 2025-03-30End: 2026-08-30Target: 380Updated: 2026-07-01
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
Not yet recruitingNCT07376382
Start: 2026-06-01End: 2029-06-06Target: 680Updated: 2026-05-13
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
Not yet recruitingNCT07406542
Start: 2026-04-01End: 2030-04-01Target: 400Updated: 2026-02-12
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
Not yet recruitingNCT07417735
Start: 2026-03-18End: 2029-12-31Target: 436Updated: 2026-02-18
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
Not yet recruitingNCT07442565
Start: 2026-03-10End: 2031-05-30Target: 506Updated: 2026-03-04
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
Not yet recruitingNCT07672223
Start: 2026-06-25End: 2031-11-30Target: 570Updated: 2026-06-26